Hanmi to Appoint Outside CEO Hwang Sang-yeon, First Outsider Chief Executive
South Korea’s Hanmi Pharmaceutical Co. is poised to appoint an external CEO, with Hwang Sang-yeon, head of private equity at HB Investment, widely regarded as the leading candidate to take the helm. If confirmed at the company’s shareholder meeting on the 31st, he would be the first chief executive recruited from outside Hanmi.
Industry reports say Hanmi’s board on the 12th named Hwang as a prospective chief executive and also appointed Kim Na-yeong, Hanmi’s head of New Product Development, as an inside director. The moves appear to set the stage for a leadership transition in the near term.
Hwang is a chemistry graduate with both bachelor’s and master’s degrees from Seoul National University. He has previously led Chong Kun Dang Holdings and Brain Asset Management, and he currently serves as head of HB Investment’s private equity division, according to industry briefings.
Separately, Hanmi’s current chief executive, Park Jae-hyun, disclosed plans to resign at the end of his term. Park’s leadership comes as he has clashed with Shin Dong-guk, chairman of Hangyang Precision, the company noted as his personal largest shareholder.
In a statement circulated after Monday’s board meeting, Park urged the preservation of Hanmi’s core values—“Im Seong-gi spirit” and “quality management”—and asked for unity in maintaining the company’s fundamentals through the transition.
Park also emphasized that any employees who supported him or participated in related actions should face no penalties, saying that he would bear all responsibility for the transition.
Meanwhile, Hanmi Science, Hanmi’s related unit, announced the appointment of Kim Nam-gyu, head of Radepang Partners, as a new non-executive outside director. Kim’s nomination is described as part of a four-party investor coalition pressuring governance changes.
Context for U.S. readers: Hanmi Pharmaceutical is a major South Korean drugmaker with global R&D and manufacturing interests. Leadership changes, especially the shift to an outside CEO and the involvement of activist-style investors, can influence strategic direction, licensing negotiations, and manufacturing quality practices that affect global supply chains and partner programs. The actions also illustrate ongoing governance reforms in Korea’s corporate landscape, with potential implications for U.S. investors and partners monitoring Korean health-care and biotech ties.